Overview

Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo

Status:
Completed
Trial end date:
2017-10-25
Target enrollment:
Participant gender:
Summary
The study shall prove whether treatment of irritable bowel syndrome with Iberogast is superior to placebo regarding the main criterium "pain"
Phase:
Phase 3
Details
Lead Sponsor:
Bayer